<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004718</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 21408</org_study_id>
    <secondary_id>NCI-2009-01348</secondary_id>
    <nct_id>NCT01004718</nct_id>
  </id_info>
  <brief_title>Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)</brief_title>
  <official_title>A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography,
      may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma
      cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and
      computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Assess the feasibility of detection and quantification of differences in the temporal and
      spatial distribution of FDG uptake between lesions of HL and DLBCL.

      OUTLINE:

      Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography
      scans 60 and 180 minutes after FDG administration.

      After completion of study, patients are followed for 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 5, 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of lesional FDG uptake</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by qualitative assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of lesional FDG uptake</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by standardized uptake value (SUV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of lesional FDG uptake</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by lesion to background update ratios at 60 and 180 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of change of lesional FDG uptake</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by change in standardized uptake value (SUV) over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characteristics of lesional standardized uptake value (SUV)</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed by frequency histograms and/or heterogeneity maps along with changes in these characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of lesion size (e.g., lesions = 3 cm) on primary outcome variables.</measure>
    <time_frame>3 months</time_frame>
    <description>Less than 3cm versus greater than or equal to 3cm impact, if any.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of lesion location on primary outcome variables (e.g., nodal vs extranodal)</measure>
    <time_frame>3 months</time_frame>
    <description>Nodal versus extranodal impact, if any.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of imaging delay time of PET image acquisition upon number of lymphomatous lesions detected</measure>
    <time_frame>3 months</time_frame>
    <description>Effect on number of lymphomatos lesions detected, if any.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Fludeoxyglucose F18 (FDG) PET/CT scans</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F18</intervention_name>
    <description>Undergo FDG PET/CT scans</description>
    <arm_group_label>Fludeoxyglucose F18 (FDG) PET/CT scans</arm_group_label>
    <other_name>18FDG, FDG, Fluorine-18, 2 Fluoro-2-deoxy-D-Glucose, Fludeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET/CT scans</description>
    <arm_group_label>Fludeoxyglucose F18 (FDG) PET/CT scans</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron emission tomography</intervention_name>
    <description>Undergo FDG PET/CT scans</description>
    <arm_group_label>Fludeoxyglucose F18 (FDG) PET/CT scans</arm_group_label>
    <other_name>FDG-PET, PET, PET scan, tomography, emission computed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable
             disease by any imaging technique or physical examination.

        Exclusion Criteria:

          -  Pregnant or nursing,

          -  Uncontrolled diabetes mellitus,

          -  Active infection,

          -  Inability to give informed consent or to comply with all study procedures,

          -  Subjects may be excluded at the discretion of the principal investigator or study team
             members.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <disposition_first_submitted>April 13, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 14, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 17, 2020</disposition_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

